ARTICLE | Clinical News
GZ402671 regulatory update
May 4, 2015 7:00 AM UTC
FDA granted Fast Track designation to GZ/SAR402671 from Sanofi’s Genzyme Corp. company to treat Fabry’s disease. The glucosylceramide synthase (GCS) inhibitor is in a Phase IIa trial for the indicat...